Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
2.
Indian J Ophthalmol ; 2007 Nov-Dec; 55(6): 460-2
Article in English | IMSEAR | ID: sea-72221

ABSTRACT

Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.


Subject(s)
Adult , Angiogenesis Inhibitors/administration & dosage , Anterior Chamber/blood supply , Antibodies, Monoclonal/administration & dosage , Blindness/complications , Female , Follow-Up Studies , Humans , Injections , Neovascularization, Pathologic/complications , Pain/complications , Time Factors , Vascular Endothelial Growth Factor A/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL